The stock of Imunon Inc (IMNN) has gone down by -4.88% for the week, with a -2.84% drop in the past month and a -21.78% drop in the past quarter. The volatility ratio for the week is 7.06%, and the volatility levels for the past 30 days are 6.00% for IMNN. The simple moving average for the past 20 days is -6.38% for IMNN’s stock, with a -30.87% simple moving average for the past 200 days.
Is It Worth Investing in Imunon Inc (NASDAQ: IMNN) Right Now?
The stock has a 36-month beta value of 2.09. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for IMNN is 13.79M, and at present, short sellers hold a 6.35% of that float. On December 27, 2024, the average trading volume of IMNN was 256.25K shares.
IMNN) stock’s latest price update
Imunon Inc (NASDAQ: IMNN) has experienced a decline in its stock price by -3.07 compared to its previous closing price of 0.81. However, the company has seen a fall of -4.88% in its stock price over the last five trading days. globenewswire.com reported 2024-12-19 that Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001 Vertical integration of major components assures a high-quality, commercially viable future manufacturing capability On track to initiate Phase 3 pivotal trial of IMNN-001 in first quarter of 2025 LAWRENCEVILLE, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) — IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, today announced the positive outcome of a Type C Chemistry, Manufacturing, and Controls (CMC) meeting with the U.S. Food and Drug Administration (FDA) regarding production of IMNN-001 for the treatment of women with newly diagnosed advanced ovarian cancer.
IMNN Trading at -7.96% from the 50-Day Moving Average
After a stumble in the market that brought IMNN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -78.36% of loss for the given period.
Volatility was left at 6.00%, however, over the last 30 days, the volatility rate increased by 7.06%, as shares sank -4.69% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.70% lower at present.
During the last 5 trading sessions, IMNN fell by -4.82%, which changed the moving average for the period of 200-days by -15.05% in comparison to the 20-day moving average, which settled at $0.8438. In addition, Imunon Inc saw 16.18% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IMNN starting from Lindborg Stacy, who purchase 25,000 shares at the price of $0.98 back on Aug 15 ’24. After this action, Lindborg Stacy now owns 264,166 shares of Imunon Inc, valued at $24,500 using the latest closing price.
Tardugno Michael H, the Executive Chairman of Board of Imunon Inc, purchase 25,000 shares at $1.03 during a trade that took place back on Aug 15 ’24, which means that Tardugno Michael H is holding 353,346 shares at $25,750 based on the most recent closing price.
Stock Fundamentals for IMNN
Current profitability levels for the company are sitting at:
- -2.97 for the present operating margin
- 0.93 for the gross margin
The net margin for Imunon Inc stands at -689.3. The total capital return value is set at -2.34. Equity return is now at value -148.12, with -99.63 for asset returns.
Currently, EBITDA for the company is -19.88 million with net debt to EBITDA at 0.45. When we switch over and look at the enterprise to sales, we see a ratio of 0.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.30.
Conclusion
To sum up, Imunon Inc (IMNN) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
